Viikinkaari 4, FIN-00790 Helsinki, Finland
F +358 9 3193 6554
News
17/06/2010
Oncolytic viruses mediating anti-tumor immunity in human cancer patients published by Oncos Therapeutics and University of Helsinki
Oncos Therapeutics, a biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published today initial results from its Advanced Therapy Access Program in Cancer Research.
03/05/2010
Biotech Business Lounge Thursday, 3th of June 2010, starting at 16:00
Helsinki Business and Science Park would like to invite you to the Biotech Business Lounge – an event to meet today’s and tomorrow’s Finnish Life Science entrepreneurs in an informal setting.
03/05/2010
Oncos Therapeutics raises € 4 million from HealthCap to develop oncolytic viruses into cancer treatments
April 29, 2010. Helsinki, Finland — Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.
29/04/2010
A Joint Biotechnology Project between Helsinki and Akron
The representatives of the cities of Helsinki and Akron (Ohio) have agreed on a joint objective to offer establishing services to life science companies. To reach the goal, the cities will create a biotechnology bridge between Helsinki and Akron.
10/07/2009
Mobidiag’s Rapid Herpesvirus Assay Now CE-IVD -marked
Prove-it™ Herpes test has achieved CE-mark for In Vitro Diagnostics (IVD) of central nervous system infections caused by herpesviruses. The PCR- and microarray-based test enables simultaneous identification of seven human herpesviruses from cerebrospinal fluid specimen in less than three hours. The rapid and comprehensive results provided by Prove-it™ Herpes are crucial to the clinicians for targeting antiviral treatment correctly. Furthermore, the coverage of the assay eliminates the need for multiple tests and thereby saves time and cuts cost in hospitals.